Rep. David Schweikert (R-Ariz.) has a strong focus on addressing the impact of diabetes in the United States. He recently spoke about federal health care spending on diabetes and its relation to the national debt. Schweikert expressed hope that both Democrats and Republicans could prioritize reducing diabetes rates and finding better treatments. However, his record contradicts his rhetoric. In the last Congress, Schweikert voted against a bipartisan bill that would have provided relief for diabetes patients struggling to afford insulin. Insulin prices have tripled in the past two decades, leading many Americans to ration their supply. While Schweikert promotes competition among drugmakers and supports nonprofit drugmakers like Civic Rx, he believes that capping insulin costs without addressing underlying prices is not a solution. Democratic opponents have criticized his voting record and accused him of insincere lecturing. Schweikert’s proposals to encourage competition and reduce drug costs remain relatively broad and he has not yet introduced legislation to effect these changes.
Insulin Caps Voted Down by GOP Lawmaker with Diabetes Obsession
Denial of responsibility! Swift Telecast is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – swifttelecast.com. The content will be deleted within 24 hours.